secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2023-09-22T23:59:59+00:00
Accession:  0001683168-23-006611
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma gets 180-day Nasdaq bid-price compliance extension to March 18, 2024
--------------------------------------------------------------------------------

- Received 180-day Nasdaq extension until March 18, 2024 to meet $1.00 min bid price.
- Company meets all other continued listing requirements except bid price.
- Intends to cure deficiency, potentially via reverse stock split if necessary.
- No immediate effect on listing or trading; common stock continues on Nasdaq under 'SBFM'.
- Compliance can be regained if closing bid price ≥$1.00 for 10 consecutive business days before deadline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823006611/0001683168-23-006611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823006611/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-006611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer